| Name | Title | Contact Details |
|---|
SciMar is a Winnipeg, MB-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
ConcertoCare is one of the nation`s leading risk-based health care companies focused on providing integrated care for seniors where they are best served: in their homes. ConcertoCare`s programs are designed for seniors with the same core, in-home care model and composed collaboratively with patients. The ConcertoCare model improves overall health quality and outcomes with a proven track record of reducing hospital admits by 47%, readmits by 40% and ER visits by 16% while achieving an increase of 38% in annual wellness visits for the most vulnerable patient populations in the U.S., benefiting patients, payers and provider networks alike. The programs are supported by a combination of in-home medical, behavioral and social services and enhanced via advanced proprietary technologies.
GetWellNetwork, Inc. is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Bethesda, MD. To find more information about GetWellNetwork, Inc., please visit www.getwellnetwork.com
Marathon Health is based in Indianapolis, IN and Winooski, VT. When we say we are a different kind of healthcare company, we mean we`re a better kind. What makes us better is that we guide people to take control of their own health. We operate on a simple premise: when people are given the tools they need to manage their own health and healthcare, the cost of healthcare is lower. We believe the best way to keep people healthy is to help them manage risk factors and chronic conditions, and to keep them from getting sick in the first place. To do this, we combine a powerful collection of onsite health services into a program tailored to your unique culture, setting, and workforce.
SCYNEXIS, Inc. is a pharmaceutical company committed to the discovery, development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. Our scientists have extensive experience in the life sciences industry having, together and individually, been involved in the discovery and development of innovative medicines over a broad range of therapy areas. We are developing our lead product candidate, SCY-078, a novel antifungal in Phase 2, as a novel oral and intravenous drug for the treatment of serious and life-threatening invasive fungal infections in humans.